GCIA
ATXS

Gabelli & Co Investment Advisers’s Astria Therapeutics ATXS Stock Holding History

Gabelli & Co Investment Advisers’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-581,550
Closed -$7.61M – 303
2025
Q4 		$7.61M Buy
+581,550
New +$6.95M 1.14% 23

Gabelli & Co Investment Advisers's ATXS Position: Q1 2026 in Review

Gabelli & Co Investment Advisers sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 581,550 shares — an estimated $7.61M sold.

Gabelli & Co Investment Advisers first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $7.61M in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • Gabelli & Co Investment Advisers reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Gabelli & Co Investment Advisers sold 581,550 Astria Therapeutics shares in Q1 2026, an estimated $7.61M.
  • Gabelli & Co Investment Advisers first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
  • Gabelli & Co Investment Advisers's Astria Therapeutics position peaked at $7.61M in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Gabelli & Co Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.